Unique Plan Description: Natalizumab (Tysabri) administration
Plan Selection Display: Natalizumab (Tysabri) administration
PlanType: Medical                                 
Version: 1          
Begin Effective Date: 2021-09-16 06:15:00
End Effective Date: 2100-12-31 00:00:00
Last Updated Date: 2021-12-20 11:18:25
Available at all facilities: No

Natalizumab (Tysabri) administration
Medications
	Tysabri
		300 mg, INT, IVPB, Once, infuse over 60 min(s), T;N
	Benadryl
		50 mg, Injection, IV Push, Once, PRN allergic reaction
	Tylenol
		1,000 mg, Tab, By Mouth, Once, PRN pain-mild
	EPINEPHrine
		0.3 mg, Injection, SUBCUTANEOUS, Once, PRN anaphylaxis
	famotidine
		20 mg, Injection, IV Push, Once, PRN dyspepsia
	sodium chloride 0.9% flush injectable soln
		20 mL, Syringe, IV Push, Once
Patient Care
	Vital Signs
		Prior to initiation of infusion and assess for any signs/symptoms of current infection, and every 30 minutes until 1 hour post infusion.  If clinically significant changes in vital signs occur, stop the infusion and notify MD.
	Notify MD
		Any abnormal baseline vital signs or Symptoms of moderate to severe reaction or severe hypersensitivity.
		T;N, Contact Provider for further orders if allergic reaction protocol initiated.
	Initiate MD Plan for:
		T;N, Allergy Reaction protocol if patient experiences reaction to treatment.

*Report Legend:
DEF - This order sentence is the default for the selected order
GOAL - This component is a goal
IND - This component is an indicator
INT - This component is an intervention
IVS - This component is an IV Set
NOTE - This component is a note
Rx - This component is a prescription
SUB - This component is a sub phase